Literature DB >> 27182820

Vaccines against respiratory syncytial virus: The time has finally come.

Barney S Graham1.   

Abstract

Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality. Published by Elsevier Ltd.

Entities:  

Keywords:  Asthma; Bronchiolitis; Elderly; Eosinophilia; Epitope; Fusion; Immunization; Infants; Neutralization; Pneumonia; Protein conformation; RSV; Structure-based vaccine design; Subunit vaccine; Th2; Vaccination; Vaccine vector; Vaccine-enhanced illness; Wheezing

Mesh：

Substances：

Year:  2016        PMID： 27182820      PMCID： PMC4912855          DOI： 10.1016/j.vaccine.2016.04.083

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  92 in total

1.  Vaccines. Structural biology triumph offers hope against a childhood killer.

Authors:  Jon Cohen
Journal:  Science       Date:  2013-11-01       Impact factor: 47.728

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

4.  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.

Authors:  R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

5.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

6.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

8.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.

Authors:  G A Prince; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Respiratory syncytial viral infection in children with compromised immune function.

Authors:  C B Hall; K R Powell; N E MacDonald; C L Gala; M E Menegus; S C Suffin; H J Cohen
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

10.  A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Authors:  Anders Krarup; Daphné Truan; Polina Furmanova-Hollenstein; Lies Bogaert; Pascale Bouchier; Ilona J M Bisschop; Myra N Widjojoatmodjo; Roland Zahn; Hanneke Schuitemaker; Jason S McLellan; Johannes P M Langedijk
Journal:  Nat Commun       Date:  2015-09-03       Impact factor: 14.919
View more
  43 in total

1.  Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Authors:  Normand Blais; Martin Gagné; Yoshitomo Hamuro; Patrick Rheault; Martine Boyer; Ann-Muriel Steff; Guy Baudoux; Vincent Dewar; Josée Demers; Jean-Louis Ruelle; Denis Martin
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Virus vs. virus: adenovirus vectored vaccine to defeat respiratory syncytial virus.

Authors:  Alessandra Vitelli; Alfredo Nicosia
Journal:  Ann Transl Med       Date:  2016-12

3.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Authors:  Jesper Pallesen; Nianshuang Wang; Kizzmekia S Corbett; Daniel Wrapp; Robert N Kirchdoerfer; Hannah L Turner; Christopher A Cottrell; Michelle M Becker; Lingshu Wang; Wei Shi; Wing-Pui Kong; Erica L Andres; Arminja N Kettenbach; Mark R Denison; James D Chappell; Barney S Graham; Andrew B Ward; Jason S McLellan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-14       Impact factor: 11.205

4.  Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children.

Authors:  Elizabeth J McFarland; Ruth A Karron; Petronella Muresan; Coleen K Cunningham; Charlotte Perlowski; Jennifer Libous; Jennifer Oliva; Patrick Jean-Philippe; Jack Moye; Elizabeth Schappell; Emily Barr; Vivian Rexroad; Laura Fearn; Mikhaela Cielo; Andrew Wiznia; Jaime G Deville; Lijuan Yang; Cindy Luongo; Peter L Collins; Ursula J Buchholz
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

5.  Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.

Authors:  Linda G Brock; Xiang Liu; Bo Liang; Matthias Lingemann; Xueqiao Liu; Richard Herbert; Ashley D Hackenberg; Ursula J Buchholz; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

Review 6.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

Review 7.  Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.

Authors:  Sara A Taleb; Asmaa A Al Thani; Khalid Al Ansari; Hadi M Yassine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-06       Impact factor: 3.267

8.  Hospitalizations Associated with Respiratory Syncytial Virus and Influenza in Children, Including Children Diagnosed with Asthma.

Authors:  Edward Goldstein; Lyn Finelli; Alissa O'Halloran; Patrick Liu; Zeynal Karaca; Claudia A Steiner; Cecile Viboud; Marc Lipsitch
Journal:  Epidemiology       Date:  2019-11       Impact factor: 4.822

9.  Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.

Authors:  Elizabeth J McFarland; Ruth A Karron; Petronella Muresan; Coleen K Cunningham; Jennifer Libous; Charlotte Perlowski; Bhagvanji Thumar; Devasena Gnanashanmugam; Jack Moye; Elizabeth Schappell; Emily Barr; Vivian Rexroad; Laura Fearn; Stephen A Spector; Mariam Aziz; Mikhaela Cielo; Christy Beneri; Andrew Wiznia; Cindy Luongo; Peter Collins; Ursula J Buchholz
Journal:  J Infect Dis       Date:  2020-02-03       Impact factor: 5.226

Review 10.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Authors:  Wen Shi Lee; Adam K Wheatley; Stephen J Kent; Brandon J DeKosky
Journal:  Nat Microbiol       Date:  2020-09-09       Impact factor: 17.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.